• 1. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 4. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 5. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471

Introduction to (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic Acid (CAS No. 852822-01-6)

(S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid, identified by its CAS number 852822-01-6, is a specialized compound with significant applications in the field of pharmaceutical chemistry and biotechnology. This compound belongs to a class of molecules that exhibit remarkable potential in the development of novel therapeutic agents. Its unique structural features, including the presence of a BENZYLOXYCARBONYLAMINO group and a 1,3-dioxolan-2-yl moiety, make it a valuable intermediate in synthetic chemistry and drug design.

The BENZYLOXYCARBONYLAMINO group is particularly noteworthy for its role as an amino protecting group in peptide synthesis. This functionality allows for selective protection of amino groups during multi-step synthetic pathways, ensuring high fidelity in the construction of complex biomolecules. The 1,3-dioxolan-2-yl substituent adds an additional layer of structural complexity, which can influence the compound's solubility, bioavailability, and overall pharmacokinetic properties. These characteristics make (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid a versatile building block for medicinal chemists.

In recent years, there has been growing interest in the development of chiral compounds for pharmaceutical applications. The stereochemical purity of (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid is particularly relevant in this context. Chiral drugs often exhibit different biological activities depending on their optical configuration, making the synthesis of enantiomerically pure compounds crucial for therapeutic efficacy. The use of this compound in drug development pipelines can lead to the creation of highly selective and effective treatments for various diseases.

Current research in the field of organic synthesis has focused on optimizing synthetic routes to improve yield and reduce costs. The synthesis of (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid has been the subject of several innovative approaches. For instance, transition metal-catalyzed reactions have been employed to streamline the introduction of the 1,3-dioxolan-2-yl group, enhancing both efficiency and scalability. These advancements not only contribute to more sustainable chemical processes but also open new avenues for the discovery of novel pharmaceuticals.

The pharmacological potential of (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid has been explored in several preclinical studies. Its structural motifs suggest possible interactions with biological targets such as enzymes and receptors involved in metabolic pathways. For example, derivatives of this compound have shown promise in inhibiting key enzymes implicated in inflammation and pain management. Such findings highlight its potential as a lead compound or intermediate in the development of next-generation therapeutics.

In addition to its pharmaceutical applications, (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid has found utility in biochemical research. Its role as a substrate or inhibitor in enzymatic assays provides valuable insights into metabolic mechanisms and enzyme function. This compound serves as a tool molecule for studying complex biological systems, contributing to our understanding of disease pathways and potential therapeutic interventions.

The future prospects for (S)-2-(BENZYLOXYCARBONYLAMINO)-5-(1,3-dioxolan-2-yl)pentanoic acid are promising, with ongoing research aimed at expanding its applications. Innovations in synthetic methodologies and computational modeling are expected to further enhance its utility in drug discovery and biotechnology. As our understanding of molecular interactions continues to evolve, this compound is poised to play an increasingly important role in the development of innovative therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)